P24011-01 Pre-Assessment

Please enable JavaScript in your browser to complete this form.
Name
Address
1. A 45-year-old with AML underwent allo-HCT and is on immunotherapy to prevent GVHD. Blood tests and imaging suggested PTLD and biopsy confirmed EBV+ PTLD. The potential burden of EBV+ PTLD in this patient is…
2. Which statement describes the current prognosis scoring systems for EBV+PTLD?
3. A 55-year-old patient underwent an auto-HCT for MM. After diagnosis of EBV+ PTLD you consider reducing immunosuppressive therapy and administering rituximab to target the EBV-infected B-cells, reduce lymph node size, and provide symptomatic relief. According to the NCCN guidelines for EBV+ PTLD, and for this patient, rituximab should be…
4. In the ALLELE trial, what was the estimated 1-year OS among patients who responded to tabelecleucel compared to non-responders (1-year OS 34.8%)?
5. A 60-year-old patient with CLL underwent an allo-HCT. She presents with persistent fever, night sweats, and unintentional weight loss. Upon diagnosis of EBV+ PTLD, you discuss tabelecleucel, a novel EBV-specific T-cell therapy, along with a reduction in immunosuppressive therapy. Based on the ALLELE trial, what are the most common grade ≥3 TEAEs you will discuss?
6. How confident are you in your ability to treat and manage patients with EBV+ PTLD?
Scroll to Top